For Eli Lilly to become the first drugmaker to soon reach that milestone market cap, it will need drugs beyond GLP-1s.
Eli Lilly became the most valuable health-care company in the world on the back of its blockbuster diabetes and obesity drugs. To join the $1 trillion market capitalization club, it will need help from the bench — including an Alzheimer's drug that moved one step closer to market this week. A key advisory panel for the Food and Drug Administration on Monday recommended donanemab, Eli Lilly's treatment for the memory-robbing disease, paving the way for full approval later this year.
A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana.Eli Lilly became the most valuable health-care company in the world on the back of its blockbuster diabetes and obesity drugs. To join the $1 trillion market capitalization club, it will need help from the bench — including an Alzheimer's drug that moved one step closer to market this week.
Pharmaceuticals Eisai Co Ltd Eisai Co Ltd Biogen Inc Eli Lilly And Co Breaking News: Markets Markets Investment Strategy Jim Cramer Stock Takes GE Healthcare Technologies Inc Business News
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Alzheimer’s drug from Eli Lilly wins backing of FDA committeeAn advisory committee to the Food and Drug Administration found the drug was safe and effective at slowing the progression of the disease, setting the stage for the agency to approve it.
Read more »
FDA advisors recommend Eli Lilly Alzheimer’s drug that slows diseaseEli Lilly's new Alzheimer's drug, donanemab, received approval from an advisory panel for the FDA. The full agency is expected to approve the drug by spring.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Read more »
Stocks making the biggest moves premarket: Eli Lilly, General Motors, ShopifyThese are the stocks posting the largest moves in premarket trading.
Read more »